Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Getein Biotech, Inc.

Getein Biotech, Inc. is a fully integrated in vitro diagnostic company that develops, manufactures and distributes an... read more Featured Products: More products

Download Mobile App





Getein Biotech Showcases Latest POCT Analyzers

By LabMedica International staff writers
Posted on 13 Nov 2024

Getein Biotech, Inc. More...

(Nanjing, China) is showcasing its latest IVD and POCT solutions at MEDICA 2024.

At this year’s MEDICA, Getein Biotech is presenting the MAGICL 6000 compact and innovative chemiluminescence immunoassay analyzer designed for mid to high-workflow laboratories that need a one-step chemiluminescence solution. Highly productive and compact, this instrument enables fully automated operation and provides the fastest testing speed of any device of its size. Alongside, Getein is highlighting the Getein 1200 immunofluorescence quantitative analyzer, a truly automated, modular, intelligent and dry system. The instrument has a low failure rate and moderate measurement speed, which is convenient for clinical departments with medium and high throughput use. Visitors to the Getein booth can also experience the Getein 1160 immunofluorescence quantitative analyzer which has four incubation channels and one emergency test channel, and a constant test environment with 32℃ to ensure more accurate test results.

Among its molecular diagnostic solutions, Getein is presenting the GN 7000 Akso PCR system, a compact and fully automated PCR lab that integrates nucleic acid release, PCR amplification, real-time detection, and result analysis to offer a one-step POCT solution for nucleic acid detection. Getein is also showcasing the Metis 6000 integrated clinical chemistry and immunochemistry modular system which is independently developed and produced. Metis 6000 integrates the MAGICL 6200 immunochemistry module (stand-alone 400 T/h) and CM-1000 clinical chemistry module (stand-alone constant speed 1000 T/h, ISE 400 T/h), and is equipped with the SH 80 sample supply track unit and SHC 200 automatic pre-analytical system. The dual module requires only 2.6m2 of space and provides customers with a more cost-effective menu of more than 180 self-generated chemistries and immunological reagents, which can be widely used in laboratories with different throughputs.

Among its range of diagnostic tests, Getein is showcasing the One Step Test for D-Dimer (Colloidal Gold) which is used as an aid in the assessment and exclusion of suspected deep vein thrombosis (DVT) or pulmonary embolism (PE) in the physical department or emergency room (ER). Additionally, the company is highlighting the Getein Cardiac Troponin l Fast Test Kit (Colloidal Gold) which is intended for the in vitro qualitative and semi-quantitative determination of cardiac Troponin l (cTnl) in serum, plasma or whole blood.

Related Links:
Getein Biotech, Inc.


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
New
Multi-Chamber Washer-Disinfector
WD 390
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.